Skip to Main Content

SYSTEMIC LUPUS ERYTHEMATOSUS

The updated 2019 diagnostic criteria for SLE require an ANA titer of 80 or more on HEp-2 cells, highlighting that SLE should almost never be diagnosed if the ANA titer is negative.

EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Mepolizumab, an IL-5 inhibitor, is FDA approved for the treatment of eosinophilic granulomatosis with polyangiitis, although it has not been studied specifically for severe life- or organ-threatening vasculitic disease manifestations (which generally require cyclophosphamide).

CRYOGLOBULINEMIA

Interferon-free direct-acting antiviral agents are preferred because of the excellent long-term response in clinical trials.

PSORIATIC ARTHRITIS

In patients with active psoriatic arthritis, a TNF inhibitor biologic agent is recommended as first-line agent.

RHEUMATOLOGIC MANIFESTATIONS OF CANCER

The persistence of some autoimmune conditions as adverse events from cancer immunotherapy despite cessation of cancer treatment, namely inflammatory arthritis, may require longterm immunosuppression.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.